Pharmacotherapy for Nonalcoholic Fatty Liver Disease

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.

Original languageEnglish
Pages (from-to)338-348
Number of pages11
JournalSeminars in Liver Disease
Volume35
Issue number3
DOIs
StatePublished - Aug 20 2015

Fingerprint

Drug Therapy
pioglitazone
Ursodeoxycholic Acid
Pentoxifylline
End Stage Liver Disease
Angiotensin Receptor Antagonists
Metformin
Unsaturated Fatty Acids
Vitamin E
Life Style
Comorbidity
Fibrosis
Non-alcoholic Fatty Liver Disease
Pharmacology
Ligands
Liver
Wounds and Injuries
Therapeutics

Keywords

  • nonalcoholic fatty liver disease
  • nonalcoholic steatohepatitis
  • obeticholic acid
  • thiazolidinedione
  • Vitamin E

ASJC Scopus subject areas

  • Hepatology

Cite this

Pharmacotherapy for Nonalcoholic Fatty Liver Disease. / Gawrieh, Samer; Chalasani, Naga.

In: Seminars in Liver Disease, Vol. 35, No. 3, 20.08.2015, p. 338-348.

Research output: Contribution to journalArticle

@article{c7bf8ecdd2b84a35b81ad14d37529812,
title = "Pharmacotherapy for Nonalcoholic Fatty Liver Disease",
abstract = "Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.",
keywords = "nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, obeticholic acid, thiazolidinedione, Vitamin E",
author = "Samer Gawrieh and Naga Chalasani",
year = "2015",
month = "8",
day = "20",
doi = "10.1055/s-0035-1562951",
language = "English",
volume = "35",
pages = "338--348",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "3",

}

TY - JOUR

T1 - Pharmacotherapy for Nonalcoholic Fatty Liver Disease

AU - Gawrieh, Samer

AU - Chalasani, Naga

PY - 2015/8/20

Y1 - 2015/8/20

N2 - Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.

AB - Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.

KW - nonalcoholic fatty liver disease

KW - nonalcoholic steatohepatitis

KW - obeticholic acid

KW - thiazolidinedione

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=84941911821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941911821&partnerID=8YFLogxK

U2 - 10.1055/s-0035-1562951

DO - 10.1055/s-0035-1562951

M3 - Article

C2 - 26378648

AN - SCOPUS:84941911821

VL - 35

SP - 338

EP - 348

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 3

ER -